Fact Sheet: Evusheld for COVID-19 Prevention

If you have a patient 12 years old or older (and at least 40 kg) who has a compromised immune system and is at high risk for COVID-19, even after vaccination, there is a preventative treatment that can help protect that patient. The U.S. Food & Drug Administration (FDA) recently issued an emergency use authorization for Evusheld, a monoclonal antibody treatment. The federal government is making the treatment available through the state.

You can learn more about Evusheld and other monoclonal therapeutic treatment options available in Ohio at the state’s COVID-19 website. The site also has information about newly authorized oral therapeutics. Patients who believe they should receive any of these treatments should talk to their healthcare provider. They require a prescription.

Unlike other treatments that are designed to help people diagnosed with COVID-19 and experiencing mild to moderate symptoms, Evusheld is intended to protect vulnerable people before they are exposed to COVID-19. According to the FDA, Evusheld is given as an injection into the muscle and may be effective for up to six months.

**Evusheld is not a substitute for vaccination.** However, this preventative treatment may provide additional protection for people with severely compromised immune systems who may not mount an adequate immune response to COVID-19 vaccination. There also are people with a history of adverse reactions to vaccines for whom the COVID-19 vaccine is not recommended. Examples of medical conditions and treatments that can lead to compromised immune systems include, but are not limited to, the following:

- Patients who are within one year of receiving B-cell depleting therapies (e.g., rituximab, ocrelizumab, ofatumumab, alemtuzumab).
- Patients receiving Bruton tyrosine kinase inhibitors.
- Chimeric antigen receptor T cell (CAR-T) recipients.
- Post-hematopoietic cell transplant recipients who have chronic graft versus host disease or who are taking immunosuppressive medications for another indication.
- Patients with hematologic malignancies who are on active therapy.
- Lung transplant recipients.
- Patients who are within one year of receiving a solid-organ transplant (other than lung transplant).
- Solid-organ transplant recipients with recent treatment for acute rejection with T or B cell depleting agents.
- Patients with severe combined immunodeficiencies.
- Patients with untreated HIV who have a CD4 T lymphocyte cell count <50 cells/mm.

Patients who think they may be eligible should talk with their healthcare provider to determine whether Evusheld is an appropriate option for them.

More information about Evusheld is available at the Ohio Department of Health’s COVID-19 website or in this fact sheet.